• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR.

作者信息

Zhang Wenli, Feng Jia, Cinquina Andrew, Wang Qingwen, Xu Haichan, Zhang Qian, Sun Lihua, Chen Qi, Xu Lei, Pinz Kevin, Wada Masayuki, Jiang Xun, Ma Yupo, Zhang Hongyu

机构信息

Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, People's Republic of China.

Research & Development Division, iCell Gene Therapeutics LLC, Long Island High Technology Incubator, 25 Health Sciences Drive, Stony Brook, NY, 11790, USA.

出版信息

Stem Cell Rev Rep. 2021 Dec;17(6):2120-2123. doi: 10.1007/s12015-021-10251-6. Epub 2021 Aug 30.

DOI:10.1007/s12015-021-10251-6
PMID:34458965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8599262/
Abstract
摘要

相似文献

1
Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR.使用BCMA-CD19复合嵌合抗原受体治疗系统性红斑狼疮。
Stem Cell Rev Rep. 2021 Dec;17(6):2120-2123. doi: 10.1007/s12015-021-10251-6. Epub 2021 Aug 30.
2
Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.系统性红斑狼疮外周血B细胞亚群上BAFF、APRIL血清水平、BAFF-R、TACI和BCMA表达与临床表现的相关性
Lupus. 2016 May;25(6):582-92. doi: 10.1177/0961203315608254. Epub 2015 Sep 29.
3
More on CD19-CAR T Cells in Systemic Lupus Erythematosus.系统性红斑狼疮中CD19嵌合抗原受体T细胞的更多研究
N Engl J Med. 2021 Nov 4;385(19):e67. doi: 10.1056/NEJMc2114593.
4
More on CD19-CAR T Cells in Systemic Lupus Erythematosus. Reply.关于系统性红斑狼疮中CD19嵌合抗原受体T细胞的更多内容。回复。
N Engl J Med. 2021 Nov 4;385(19):e67. doi: 10.1056/NEJMc2114593.
5
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.复发或难治性多发性骨髓瘤患者中人性化抗CD19和抗BCMA嵌合抗原受体T细胞的联合应用：一项单臂2期试验
Lancet Haematol. 2019 Oct;6(10):e521-e529. doi: 10.1016/S2352-3026(19)30115-2. Epub 2019 Aug 1.
6
Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation.狼疮患者的 BCMA 表达增加，表明激活的 B 细胞增多，BCMA 受体的结合增强了对 TLR9 刺激的反应。
Autoimmunity. 2011 Mar;44(2):69-81. doi: 10.3109/08916934.2010.509122. Epub 2011 Jan 20.
7
Abnormal expression of BAFF and its receptors in peripheral blood and skin lesions from systemic lupus erythematosus patients.系统性红斑狼疮患者外周血和皮损中 BAFF 及其受体的异常表达。
Autoimmunity. 2020 Jun;53(4):192-200. doi: 10.1080/08916934.2020.1736049. Epub 2020 Mar 11.
8
[Modulating the survival and maturation system of B lymphocytes: Current and future new therapeutic strategies in systemic lupus erythematosus].[调节B淋巴细胞的存活和成熟系统：系统性红斑狼疮当前及未来的新治疗策略]
Med Clin (Barc). 2015 Sep 7;145(5):206-10. doi: 10.1016/j.medcli.2014.08.008. Epub 2014 Nov 26.
9
Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis.意向治疗与 B 细胞成熟抗原和 CD19 嵌合抗原受体试验的改良意向治疗分析：系统评价和荟萃分析。
Eur J Cancer. 2021 Oct;156:164-174. doi: 10.1016/j.ejca.2021.07.036. Epub 2021 Aug 26.
10
TACI-dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus.在系统性红斑狼疮小鼠模型中，TACI 依赖的 APRIL 信号传导维持自身反应性 B 细胞。
Eur J Immunol. 2017 Apr;47(4):713-723. doi: 10.1002/eji.201646630.

引用本文的文献

1
CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases.嵌合抗原受体T细胞（CAR-T）疗法：开创自身免疫性疾病治疗的新时代。
Front Immunol. 2025 Aug 13;16:1625166. doi: 10.3389/fimmu.2025.1625166. eCollection 2025.
2
Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now?嵌合抗原受体T细胞免疫疗法治疗自身免疫性风湿性疾病：我们目前的进展如何？
Cells. 2025 Aug 12;14(16):1242. doi: 10.3390/cells14161242.
3
Breaking boundaries in ankylosing spondylitis: how innovative cell therapies reshape immunity, drive cutting-edge advances, and face future challenges.
强直性脊柱炎领域的突破：创新细胞疗法如何重塑免疫、推动前沿进展并应对未来挑战。
Front Immunol. 2025 Jul 11;16:1613502. doi: 10.3389/fimmu.2025.1613502. eCollection 2025.
4
Immune cell aberrations in Systemic Lupus Erythematosus: navigating the targeted therapies toward precision management.系统性红斑狼疮中的免疫细胞异常：靶向治疗走向精准管理
Cell Mol Biol Lett. 2025 Jun 16;30(1):73. doi: 10.1186/s11658-025-00749-z.
5
From myth to bedside: a scoping review of the applications of the chimeric antigen receptor in rheumatology.从神话到临床：嵌合抗原受体在风湿病学应用的范围综述
Clin Exp Med. 2025 Jun 6;25(1):189. doi: 10.1007/s10238-025-01717-9.
6
CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?嵌合抗原受体T细胞疗法用于青少年起病的自身免疫性疾病：前景可期？
Arthritis Res Ther. 2025 May 10;27(1):102. doi: 10.1186/s13075-025-03564-1.
7
Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy.免疫介导的炎症性疾病：从靶向生物疗法、干细胞疗法到靶向细胞疗法。
Front Immunol. 2025 Apr 7;16:1520063. doi: 10.3389/fimmu.2025.1520063. eCollection 2025.
8
Cellular therapies in rheumatic and musculoskeletal diseases.风湿性和肌肉骨骼疾病的细胞疗法。
J Transl Autoimmun. 2024 Dec 16;10:100264. doi: 10.1016/j.jtauto.2024.100264. eCollection 2025 Jun.
9
Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases.用于自身免疫性疾病和其他非肿瘤性疾病的工程化T细胞免疫疗法的进展。
Biomark Res. 2025 Feb 4;13(1):23. doi: 10.1186/s40364-025-00736-8.
10
Opportunities and limitations of B cell depletion approaches in SLE.系统性红斑狼疮中B细胞清除疗法的机遇与局限
Nat Rev Rheumatol. 2025 Feb;21(2):111-126. doi: 10.1038/s41584-024-01210-9. Epub 2025 Jan 15.